The majority of these studies were published, however, prior to the wide adoption of GLP-1 (glucagon-like peptide-1) analogs as a cornerstone in the management of T2D, which may further represent a gross representation of the reality of gastroparesis in individuals with diabetes [18]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.